SCYNEXIS, Inc. (SCYX)
| Market Cap | 54.44M +42.1% |
| Revenue (ttm) | 20.34M +673.5% |
| Net Income | -24.52M |
| EPS | -0.49 |
| Shares Out | 79.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 631,240 |
| Open | 0.7300 |
| Previous Close | 0.7400 |
| Day's Range | 0.6700 - 0.7350 |
| 52-Week Range | 0.5650 - 1.3100 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 4.19 (+511.41%) |
| Earnings Date | May 11, 2026 |
About SCYX
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in... [Read more]
Financial Performance
In 2025, SCYNEXIS's revenue was $20.60 million, an increase of 449.95% compared to the previous year's $3.75 million. Losses were -$8.61 million, -59.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SCYX stock is "Strong Buy." The 12-month stock price target is $4.19, which is an increase of 511.41% from the latest price.
News
Scynexis reports Q1 EPS (42c), consensus (12c)
Cash, cash equivalents and investments totaled $72.4M on March 31, compared to $56.3M on December 31, 2025. The balance at March 31 includes approximately $24M of the gross proceeds of…
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today re...
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address sever...
Scynexis files to sell 87M shares of common stock for holders
16:04 EDT Scynexis (SCYX) files to sell 87M shares of common stock for holders
SCYNEXIS Transcript: M&A announcement
Acquisition of SCY-770 marks a strategic shift to rare renal diseases, targeting ADPKD with a promising, selective AMPK activator. The deal provides global rights, strong IP, and financial runway to 2029, positioning the company for leadership in a large, underserved market.
Poxel announces sale of PXL770 to Scynexis for up to $196M
POXEL (PXXLF) entered into a definitive agreement with SCYNEXIS (SCYX) in connection with the sale of its drug candidate PXL770. PXL-770 is a novel, highly selective, direct AMPK activator developed…
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with...
Scynexis completes acquisition of PXL-770 for treatment of kidney disease
Scynexis (SCYX) has entered into a definitive agreement with Poxel to acquire PXL-770 – now SCY-770 -. SCY-770 is a novel, highly selective, direct AMP-activated protein kinase, or AMPK, activator…
Scynexis announces $40M private placement
Scynexis (SCYX) announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The company anticipates upfront gross proceeds ...
SCYNEXIS Announces $40.0 Million Private Placement
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address s...
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concep...
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista...
Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247
SCYNEXIS (SCYX) announced that the first participants have been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generati...
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...
Cero Therapeutics appoints Eric Francois to board of directors
CERo Therapeutics Holdings (CERO) announces the appointment of Eric Francois to the Company’s Board of Directors. Formerly, he served as CFO of SCYNEXIS (SCYX).
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targe...
Scynexis announces presentation highlighting data from SCY-247
Scynexis (SCYX) announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resis...
Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247
Scynexis (SCYX) announced that the U.S. Food and Drug Administration, FDA, has granted the Company Qualified Infectious Disease Product, QIDP, and Fast Track Designations, FTD, for its second-generati...
Scynexis granted 180-day extension by Nasdaq to regain compliance
SCYNEXIS (SCYX) announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market to regain compliance with the minimum bid price requirement, as outlined in Nasdaq ...
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...
Scynexis completes transfer of BREXAFEMME NDA to GSK
SCYNEXIS (SCYX) announced that it has completed the transfer of the BREXAFEMME New Drug Application, NDA, to GSK (GSK). “We are pleased to announce this important milestone for SCYNEXIS. With…
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
SCYNEXIS (SCYX) announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded t...
Scynexis reports Q3 EPS (17c), consensus (20c)
Reports Q3 revenue $334,000, consensus $147,670. “Over the last several weeks, SCYNEXIS (SCYX) realized two significant achievements that we believe position our company for significant growth and suc...
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...